Opaleye Management’s Fennec Pharmaceuticals FENC Stock Holding History

Opaleye Management’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-272,200	Closed	-$2.61M	–	44
2022 Q4	$2.61M	Buy	+272,200	New	+$2.41M	0.91%	32
2020 Q3	–	Sell	-171,000	Closed	-$1.43M	–	62
2020 Q2	$1.43M	Buy	+171,000	New	+$1.27M	0.29%	43
2020 Q1	–	Sell	-12,000	Closed	-$78K	–	48
2019 Q4	$78K	Buy	+12,000	New	+$64.5K	0.02%	45
2019 Q3	–	Sell	-295,000	Closed	-$1.18M	–	52
2019 Q2	$1.18M	Sell	295,000 -335,000	-53%	-$1.42M	0.36%	38
2019 Q1	$3.06M	Sell	630,000 -270,000	-30%	-$1.78M	0.85%	41
2018 Q4	$5.74M	Sell	900,000 -75,000	-8%	-$524K	2.14%	15
2018 Q3	$8M	Buy	975,000 +30,000	+3%	+$278K	2.03%	17
2018 Q2	$9.87M	Buy	945,000 +72,000	+8%	+$854K	2.55%	11
2018 Q1	$10.6M	Buy	873,000 +26,100	+3%	+$247K	3.02%	9
2017 Q4	$8.49M	Buy	+846,900	New	+$8.45M	2.72%	12

Other funds holding FENC

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Opaleye Management's FENC Position: Q1 2023 in Review

Opaleye Management sold out of Fennec Pharmaceuticals (FENC) in Q1 2023, closing a stake of 272,200 shares — an estimated $2.61M sold.

Opaleye Management first reported a position in FENC in Q4 2017 and held it in 10 quarters. The position peaked at $10.6M in Q1 2018. 53 funds tracked by Wall St. Rank hold FENC as of Q1 2023.

Opaleye Management reported no remaining Fennec Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Opaleye Management sold 272,200 Fennec Pharmaceuticals shares in Q1 2023, an estimated $2.61M.
Opaleye Management first reported a position in Fennec Pharmaceuticals in Q4 2017 and held it in 10 quarters.
Opaleye Management's Fennec Pharmaceuticals position peaked at $10.6M in Q1 2018.
53 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2023.

Based on Opaleye Management's 13F filing for Q1 2023, filed 15 May 2023.